These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17179105)

  • 1. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
    Pashenkov M; Goëss G; Wagner C; Hörmann M; Jandl T; Moser A; Britten CM; Smolle J; Koller S; Mauch C; Tantcheva-Poor I; Grabbe S; Loquai C; Esser S; Franckson T; Schneeberger A; Haarmann C; Krieg AM; Stingl G; Wagner SN
    J Clin Oncol; 2006 Dec; 24(36):5716-24. PubMed ID: 17179105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
    Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
    J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
    Dummer R; Hauschild A; Becker JC; Grob JJ; Schadendorf D; Tebbs V; Skalsky J; Kaehler KC; Moosbauer S; Clark R; Meng TC; Urosevic M
    Clin Cancer Res; 2008 Feb; 14(3):856-64. PubMed ID: 18245549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
    Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
    Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
    ; Celis E
    Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
    Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
    Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
    Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
    Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
    Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
    Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
    Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
    Tuettenberg A; Schmitt E; Knop J; Jonuleit H
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes.
    Matsumoto K; Kubo H; Murata H; Uhara H; Takata M; Shibata S; Yasue S; Sakakibara A; Tomita Y; Kageshita T; Kawakami Y; Mizuno M; Yoshida J; Saida T
    Jpn J Clin Oncol; 2008 Dec; 38(12):849-56. PubMed ID: 18945721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha.
    Schroeder JT; Chichester KL; Bieneman AP
    J Allergy Clin Immunol; 2008 Feb; 121(2):486-91. PubMed ID: 18036648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
    McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
    Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.